Cingulate Inc. (CING) vs Kalaris Therapeutics Inc (KLRS)
A side-by-side comparison of Cingulate Inc. and Kalaris Therapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CING
Cingulate Inc.
$4.90HealthcareDelayed quote: Oct 6, 2026, 11:57 AM EDT
KLRS
Kalaris Therapeutics Inc
$2.87HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
Total return — CING vs KLRS
growth of $100 · dividends reinvested · last 5yCING -99.6% (-66.1%/yr)KLRS -100.0% (-80.8%/yr)CING compounded faster over this window
Log scale — wide-divergence pair
CING KLRS
CING vs KLRS: by the numbers
- •CING is the larger company ($66M vs $63M market cap).
Metrics side by side
Valuation
| Metric | CING | KLRS |
|---|---|---|
| P/B ratio | 2.81 | 1.08 |
| EV / EBITDA | 0.23 | N/A |
Profitability
| Metric | CING | KLRS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -122.71% | -76.75% |
| ROIC | -83.74% | -52.40% |
Growth (annualized)
| Metric | CING | KLRS |
|---|---|---|
| Total return CAGR (5Y) | N/A | -81.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.